11.09.2022, 747 Zeichen

Valneva: Valenva, an Austrian/French specialty vaccine company, announced that The Lancet Infectious Diseases (“The Lancet ID”), a peer-reviewed medical journal, has published the Company’s pivotal Phase 3 clinical data for its inactivated, whole-virus COVID-19 vaccine, VLA2001.Juan Carlos Jaramillo, Chief Medical Officer of Valneva, said, “This Lancet publication is a strong scientific and developmental validation of the work that has been accomplished at Valneva. We are pleased that more detailed results on our inactivated COVID-19 vaccine are now available to the scientific and broader public health communities.”
Valneva: weekly performance: 1.90%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (05/09/2022)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #793: Pierer Mobility kräftig im Plus, Sparplan-Festival bei der EAM, mein wikifolio Case eines CFA Awards

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, voestalpine, Amag, Immofinanz, CA Immo, EuroTeleSites AG, Frequentis, Rosgix, Warimpex, Wienerberger, Kapsch TrafficCom, AT&S, Frauenthal, Gurktaler AG Stamm, Polytec Group, Wolftank-Adisa, Porr, Oberbank AG Stamm, UBM, Palfinger, Zumtobel, Addiko Bank, Agrana, Erste Group, EVN, Flughafen Wien, OMV, Österreichische Post, S Immo, Telekom Austria, Uniqa.

---